ARK Genomic Revolution ETF

ARK Genomic Revolution ETF (ARKG) is an actively managed fund from ARK Invest. It holds a concentrated group of genomics companies, such as 10x Genomics, Twist Bioscience and CRISPR Therapeutics. Its fee is 0.75% a year, above the 0.57% average of similar funds. Its price swings are extreme: it fell 83.6% from January 2021 to April 2025, then rose 78.3% from the start of 2026 through October 27, 2026.

• Over the year to Oct 27, 2026, ARKG returned +65.8%, 1st of 6 among similar funds.
• Its 5-year annualized return was -6.8% and its 10-year +12.5%.
• In the 2020 COVID crash it fell 35% and regained its old high 1.1 months after the low.
• Its worst full calendar year was 2022 (-53.9%); its best was 2020 (+180.6%).
• The deepest fall in its price history was 83.6% (Jan 20, 2021 to Apr 8, 2025), not yet recovered.

As of Jul 31, 2026, the fund held 32 securities; the ten largest made up 59.05% of assets.

• Over the three months to Jul 31, 2026, investors withdrew a net $3.3M (creations minus redemptions, per the N-PORT report).
• Monthly total returns reported for that quarter: +15.83%, +21.56%, -8.30%.

ARKG does not track an index. It is actively managed, which means ARK Invest's managers pick the stocks. At least 80% of its assets go to what ARK calls Genomic Revolution Companies. These are firms that ARK believes focus on, and will benefit from, genomics, which is the study of genes and how they work. Examples include gene sequencing (reading DNA), analysis and synthesis, along with bioinformatics, molecular medicine and agricultural biotechnology. Some holdings may not yet earn much of their revenue from genomics.

The managers use two kinds of research. "Top down" research estimates how large a market could become. "Bottom up" research looks at each company's valuation and fundamentals. ESG (environmental, social and governance) factors are part of the analysis, but they are not used to exclude companies. The fund leans toward ARK's highest-conviction ideas. The prospectus sets no fixed rebalancing schedule, and the fund's portfolio turnover was 33%.

The portfolio is concentrated by design. More than 25% of the fund sits in health care stocks. It is also "non-diversified," which means it can put a large share of its money into a few companies, typically about 35 to 50 of them. As of July 31, 2026, it held 32 stocks, and the top 10 made up 59% of assets. About 90% was in US companies, with the rest in Switzerland and the UK. The fund held no derivatives and almost no cash.

• ARKG charges 0.75% a year, versus an average of 0.57% for the similar funds below (5th of 6, cheapest first).
• Using the prospectus's standard example, $10,000 invested would cost about $77 in the first year and $930 over 10 years (assuming a 5% annual return).

ARKG is a narrow, actively managed bet on genomics with very large swings and no income, so it fits only as a small add-on to a diversified core.

ARKG gives targeted exposure to genomics firms, but the losses have been severe. The fund launched in 2014, so it has no record from 2008. In the 2020 COVID crash it fell 35% in ten days and recovered within about a month. In the 2022 bear market it fell 57%, and 2022 was its worst calendar year, at -53.9%. Its deepest drop was 83.6%, from January 2021 to April 2025, and it had not recovered as of October 27, 2026. Someone who has to sell in a bad year could lock in large losses. The fund paid no distributions in the year to October 27, 2026, so it provides no income. It costs 0.75% a year, or $77 in the first year in the SEC's standard $10,000 example. Past results don't predict future ones, and a plan should look at the whole portfolio, not one fund.

Matched by holdings overlap from the latest N-PORT reports.